Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on ...

Rapidly mutating DNA regions were mapped using a multi-generational family and advanced sequencing tools. Understanding how ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close.

PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 15 cents in first-quarter 2025, narrower than the year-ago adjusted loss of 26 ...

GAAP net loss for the first quarter of 2025 was $426.1 million, compared to $78.2 million for the first quarter of 2024.

PacBio has announced the conclusion of its Special Committee's independent investigation into allegations related to employment practices and cybersecurity raised by an attorney for a former ...

Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life ...

CEO Christian Henry reported Q1 2025 revenue of $37.2 million, aligning with internal expectations. Instrument revenue was $11 million, with 12 Revio and 28 Vega systems shipped during the quarter ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations , but sales fell by 4.3% year on year to $37.15 million.

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system ...

Updates since PacBio's last earnings release Initiated a company-wide restructuring plan to reduce operating expenses and sharpen our strategic focus to concentrate resources on the long-read ...